Recursion Pharmaceuticals Inc (RXRX)
7.95
+0.25
(+3.25%)
USD |
NASDAQ |
Apr 24, 16:00
7.80
-0.15
(-1.89%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash from Investing (TTM): -10.23M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -10.23M |
| September 30, 2023 | -15.72M |
| June 30, 2023 | 37.61M |
| March 31, 2023 | 44.60M |
| December 31, 2022 | 193.25M |
| September 30, 2022 | 148.98M |
| June 30, 2022 | -97.87M |
| Date | Value |
|---|---|
| March 31, 2022 | -109.02M |
| December 31, 2021 | -271.74M |
| September 30, 2021 | -224.09M |
| June 30, 2021 | -33.64M |
| March 31, 2021 | -27.47M |
| December 31, 2020 | -8.74M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-271.74M
Minimum
Dec 2021
193.25M
Maximum
Dec 2022
-28.78M
Average
-15.72M
Median
Sep 2023
Cash from Investing (TTM) Benchmarks
| Eli Lilly and Co | -7.153B |
| Palatin Technologies Inc | 9.293M |
| Oragenics Inc | -0.9363M |
| Editas Medicine Inc | -3.731M |
| BioXcel Therapeutics Inc | -0.02M |